Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activ

Autor: Julie Qidwai, E. Mark Haacke, Michael T. Froehler, Jan Claassen, Curtis G. Benesch, Arthur W. Toga, Ashutosh P Jadhav, Howard P. Levy, Shlee S. Song, Kim Magee, Robert N. Sawyer, Marilyn M Rymer, Michael A. Rippee, Archana Hinduja, Thomas P. Davis, Mark Johnson, Merit Cudkowicz, Michel T. Torbey, Miller Fawaz, Kent E. Pryor, Peter M Hannon, Patrick D. Lyden, Opeolu Adeoye, Berislav V. Zlokovic, E. Clarke Haley, Jon W. Yankey, Robin Conwit, John H. Griffin, Jin-Moo Lee, Natalia S. Rost, Christopher S. Coffey

Publikováno v: Annals of Neurology. 85:125-136

Objective Agonism of protease-activated receptor (PAR) 1 by activated protein C (APC) provides neuro- and vasculoprotection in experimental neuroinjury models. The pleiotropic PAR1 agonist, 3K3A-APC, reduces neurological injury and promotes vascular

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a0615fcf4bdf9592506a9a2f91a891
https://doi.org/10.1002/ana.25383

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials

Autor: Jean Baptiste Le Pichon, Stephanie Lowenhaupt, Jessica Lamb, Eric D. Foster, Patricia K. Coyle, Mariam Andersen, Christine Annis, Alexander J. Stein, Angela Molloy, Tracy A. Glauser, Laurie Gutmann, Steven M. Greenberg, Mengesha Teshome, A. Gordon Smith, Richard J. Barohn, Paula R. Clemens, Susan T. Iannaccone, Robert G. Holloway, Carole Seeley, Luis J. Mejico, Audrey Ellis, Bjorn Oskarsson, Jeremy M. Shefner, Emine O. Bayman, R. Peters, Anthony A. Amato, Louis B. Nabors, Beth A. Malow, Blagovest Nikolov, Mark Quigg, Claudia A. Chiriboga, Peggy Clark, Christine L. Amity, Mark P. Goldberg, Joseph F. Quinn, Trevis Huff, E. Clarke Haley, Codrin Lungu, Kellie Keith, David B. Clifford, Julie Steele, Stephen J. Kolb, Michael Benatar, Muhammad Maaz Iqbal, Shlomo Shinnar, Lawrence R. Wechsler, Basil T. Darras, Melanie Benge, Robin Conwit, Tanya Simuni, Catherine P. Canamar, Timothy Vollmer, Roger J. Packer, Michael Bosch, Khurram Bashir, Sara DeGregorio, Karen W. Adkins, James Bowen, Tina Ward, Dixie Ecklund, Marianne Chase, Bruce H. Dobkin, Stewart A. Factor, Gil I. Wolfe, Katy Mahoney, James C. Torner, Donna Patch, Mariana Doudova, Amy Bartlett, Nadege Gilles, Jeffrey D. Long, Caryl Tongco, Karen Marder, Claire Henchcliffe, Joyce Ann Moran, Mazen M. Dimachkie, Jon W. Yankey, Merit Cudkowicz, J. Robinson Singleton, Craig M. McDonald, Christopher S. Coffey, Annemarie Crumlish, Noreen L. Connolly, Brenda Thornell, John T. Kissel, Steven R. Levine, Kevin J. Staley, Erik K Henricson, Daniel Woo

Publikováno v: JAMA Neurol

Importance One major advantage of developing large, federally funded networks for clinical research in neurology is the ability to have a trial-ready network that can efficiently conduct scientifically rigorous projects to improve the health of peopl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5044f10b372c073d4f66f43230f9e21
https://doi.org/10.1001/jamaneurol.2020.0367

Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial

Autor: Mikael Mazighi, Joseph P. Broderick, Pooja Khatri, Yuko Y. Palesch, Andrew M. Demchuk, Mayank Goyal, Michael D. Hill, Pierre Amarenco, Lydia D. Foster, Sharon D. Yeatts, Achala Vagal, Edward C. Jauch, E. Clarke Haley, Janice Carrozzella, Judith Spilker, Thomas A. Tomsick, David S Liebeskind

Publikováno v: The Lancet Neurology. 13:567-574

Summary Background The IMS III trial did not show a clinical benefit of endovascular treatment compared with intravenous alteplase (recombinant tissue plasminogen activator) alone for moderate or severe ischaemic strokes. Late reperfusion of tissue t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9930bf692fe8ca7d816d3e6ccda81a9f
https://doi.org/10.1016/s1474-4422(14)70066-3

Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design

Autor: John L.P. Thompson, Bibhas Chakraborty, Robert B. MacArthur, E. Clarke Haley, Gilberto Levy, Bruce Levin

Publikováno v: Clinical Trials (London, England)

Background TNK-S2B, an innovative, randomized, seamless phase II/III trial of tenecteplase versus rt-PA for acute ischemic stroke, terminated for slow enrollment before regulatory approval of use of phase II patients in phase III. Purpose (1) To revi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b98eebea7c6d39f258e87b181585f4f8
https://doi.org/10.1177/1740774511410582

Recombinant Tissue Plasminogen Activator for Minor Strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Experience

Autor: Corsee Sanders, Patrick D. Lyden, Thomas G. Brott, Joseph P. Broderick, Yan Lin, Thomas Kwiatkowski, Scott Hamilton, Michael Frankel, James C. Grotta, John R. Marler, E. Clarke Haley, Lewis B. Morgenstern, Christopher Lewandowski, Mei Lu, Steven R. Levine, Susan C. Fagan, Richard B. Libman, Suresh C. Patel, Thomas J. DeGraba, Barbara C. Tilley

Publikováno v: Annals of Emergency Medicine. 46:243-252

Acute ischemic stroke patients eligible for tissue plasminogen activator and with less severe neurologic deficits, although still generally benefiting from therapy, may have a different risk-benefit profile than all eligible acute stroke patients. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bce78179efcf1d697b0dc3de2a52bde
https://doi.org/10.1016/j.annemergmed.2005.02.013